Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Nausea, felt nauseous; Tiredness, felt tired; late dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of nausea in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on 24-FEB-2020). On 13-AUG-2025, the patient received the 2nd dose of Shingrix. On 13-AUG-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: late dose). On an unknown date, the patient experienced nausea (Verbatim: Nausea, felt nauseous) and tiredness (Verbatim: Tiredness, felt tired). The outcome of the nausea and tiredness were unknown and the outcome of the drug dose administration interval too long was not applicable. It was unknown if the reporter considered the nausea and tiredness to be related to Shingrix. It was unknown if the company considered the nausea and tiredness to be related to Shingrix. Additional Information: GSK Receipt Date: 19-SEP-2025 Reporter was the patient who received first dose on 24-Feb-2020 and then second dose on 13-Aug-2025. Patient also felt nauseous and tired after second dose.